Summary
Clinical trials using interleukin 2 as a therapeutic immunomodulating agent in patients with acquired immunodeficiency syndrome have recently begun. In this article we present data from studies which indicate the ability of interleukin 2in vitro to augment clinically important cytotoxic immune responses in lymphocytes from these patients. These studies provide both a rationale for the current trials and a model for evaluating the potential for use of interleukin 2 in other infectious diseases. We outline the types of infectious diseases in which interleukin 2 may prove to be useful and the therapeutic strategies in which it may play a role.
Zusammenfassung
Vor kurzem wurden klinische Versuche mit Interleukin 2 als immunmodulierendes Therapeutikum bei Patienten mit erworbenem Immundefektsyndrom begonnen. Aus den in dieser Arbeit vorgestellten Untersuchungsergebnissen ist abzuleiten, daß Interleukin 2in vitro zytotoxische Immunantworten von Lymphozyten dieser Patienten verstärkt, die klinisch bedeutsam sind. Diese Untersuchungen bilden die Basis für die laufenden Studien und stellen gleichzeitig ein Modell für die Beurteilung der therapeutischen Wertigkeit von Interleukin 2 bei anderen Infektionen dar. Wir grenzen die Typen von Infektionskrankheiten ab, bei denen Interleukin 2 nützlich sein könnte, sowie die therapeutischen Strategien, in denen Interleukin 2 möglicherweise eine Rolle zukommt.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literature
Farrar, J. J., Benjamin, W. R., Hilfiker, M. L., Howard, M., Farrar, W. L., Fuller-Farrar, J. The biochemistry, biology, and role of interleukin-2 in the induction of cytotoxic T cell and antibody-forming B cell responses. Immunol. Rev. 63 (1982) 129–166.
Kasahara, T., Djeu, J. Y., Dougherty, S. F., Oppenheim, J. J. Capacity of human larger granular lymphocytes (LGL) to produce multiple lymphokines: interleukin-2, interferon and colony stimulating factor. J. Immunol. 131 (1983) 2379–2385.
Henney, C. S., Kuribayashi, K., Kern, D. E., Gillis, S. Interleukin-2 augments natural killer cell activity. Nature 291 (1981) 335–338.
Grimm, E. A., Mazumder, A., Zhang, H. Z., Rosenberg, S. A. Lymphokine activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155 (1982) 1823–1841.
Taniguchi, T., Matsui, H., Fujita, T., Takaoka, C., Kashima, N., Yoshimoto, R., Hamuro, J. Structure and expression of a cloned cDNA for human interleukin-2. Nature 302 (1983) 305–310.
Quinnan, G. V., Jr., Masur, H., Rook, A. H., Armstrong, G., Frederick, W. J. R., Fauci, A. S., Ames, J., Epstein, J. S., Lane, H. C., Macher, A. M., Manischewitz, J. F., Jackson, L., Smith, K. A., Parker, M., Pearson, G. R., Parillo, J., Straus, S.: Herpes virus infections in the acquired immunodeficiency syndrome. JAMA (1984) in press.
Macher, A. M., Reichert, D., Straus, S., Longo, D. L., Parillo, J., Lane, H. C., Fauci, A. S., Rook, A. H., Manischewitz, J. F., Quinnan, G. V., Jr. Death in the AIDS patient: role of cytomegalovirus. N. Engl. J. Med. 309 (1983) 1454.
Quinnan, G. V., Jr., Rook, A. H., Frederick, W. J. R., Manischewitz, J. F., Epstein, J. S., Siegel, J. P., Masur, H., Macher, A. M., Djeu, J. Y.: Prevalence, clinical manifestations, and immunology of herpes virus infections in the acquired immunodeficiency syndrome. Ann. N. Y. Acad. Sci. (1984) in press.
Rook, A. H., Quinnan, G. V., Jr., Frederick, W. J. R., Manischewitz, J. F., Kirmani, N., Dantzler, T., Lee, B. B., Currier, C. B., Jr. Importance of cytotoxic lymphocytes during cytomegalovirus infection of renal transplant recipients. Am. J. Med. 76 (1984) 385–392.
Quinnan, G. V., Jr., Kirmani, N., Rook, A. H., Manischewitz, J. F., Jackson, L., Moreschi, G., Santos, G. W., Saral, R., Burns, W. H. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N. Engl. J. Med. 307 (1982) 7–13.
Rook, A. H., Masur, H., Lane, H. C., Frederick, W. J. R., Kasahara T., Macher, A. M., Djeu, J. Y., Manischewitz, J. F., Jackson, L., Fauci, A. S., Quinnan, G. V., Jr. Interleukin-2 enhances the depressed natural killer cell and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immunodeficiency syndrome. J. Clin. Invest. 72 (1983) 398–403.
Siegel, J. P., Djeu, J. Y., Stocks, N. I., Masur, H., Fauci, A. S., Lane, H. C., Gelmann, E. P., Quinnan, G. V., Jr.: Serum from patients with the acquired immunodeficiency syndrome (AIDS) suppresses production of interleukin-2 by normal peripheral blood lymphocytes. Clin. Res. (1984) 358A.
Quinnan, G. V., Jr., Delery, M., Rook, A. H., Frederick, W. J. R., Epstein, J. S., Manischewitz, J. F., Jackson, L., Ramsey, K. M., Mittal, K., Plotkin, S. A., Hilleman, M. R.: Comparative virulence and immunogenicity of the Towne strain and a non-attenuated strain of cytomegalovirus. Ann. Intern. Med. (1984) in press.
Zagury, D., Morgan, D., Lenoir, G., Fouchard, M., Feldman, M. Human normal CTL clones: generation and properties. Int. J. Cancer 31 (1983) 427–432.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Siegel, J.P., Rook, A.H., Djeu, J.Y. et al. Interleukin 2 therapy in infectious diseases: Rationale and prospects. Infection 13 (Suppl 2), S219–S223 (1985). https://doi.org/10.1007/BF01644434
Issue Date:
DOI: https://doi.org/10.1007/BF01644434